9.21
0.20 (2.22%)
| Penutupan Terdahulu | 9.01 |
| Buka | 8.94 |
| Jumlah Dagangan | 948,039 |
| Purata Dagangan (3B) | 1,445,126 |
| Modal Pasaran | 558,035,904 |
| Harga / Jualan (P/S) | 2.62 |
| Harga / Buku (P/B) | 0.940 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -198.84% |
| Margin Operasi (TTM) | -182.09% |
| EPS Cair (TTM) | -8.91 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 27.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 67.12% |
| Nisbah Semasa (MRQ) | 4.88 |
| Aliran Tunai Operasi (OCF TTM) | -281.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -185.65 M |
| Pulangan Atas Aset (ROA TTM) | -16.99% |
| Pulangan Atas Ekuiti (ROE TTM) | -57.76% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Ginkgo Bioworks Holdings, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -4.0 |
| Purata | -0.63 |
|
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 6.88% |
| % Dimiliki oleh Institusi | 77.96% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Erste Asset Management Gmbh | 30 Sep 2025 | 2,200,000 |
| Anchorage Capital Group, L.L.C. | 30 Sep 2025 | 1,746,363 |
| Forbes J M & Co Llp | 30 Sep 2025 | 1,060,341 |
| Ensign Peak Advisors, Inc | 30 Sep 2025 | 335,073 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Dec 2025 | Pengumuman | STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy |
| 18 Nov 2025 | Pengumuman | Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health |
| 06 Nov 2025 | Pengumuman | Ginkgo Bioworks Reports Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Pengumuman | Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium |
| 31 Oct 2025 | Pengumuman | Ginkgo Bioworks and Bayer Extend Multi-Year Strategic Partnership to Accelerate Next Generation Biological Solutions for Agriculture |
| 30 Oct 2025 | Pengumuman | Ginkgo Bioworks Announces Date of Third Quarter 2025 Results Presentation |
| 23 Oct 2025 | Pengumuman | Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |